Valence8 US LP Invests $103,000 in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Valence8 US LP purchased a new stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 34,376 shares of the company’s stock, valued at approximately $103,000.

A number of other hedge funds have also modified their holdings of the company. American Century Companies Inc. increased its stake in Vistagen Therapeutics by 49.1% in the second quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock valued at $105,000 after purchasing an additional 9,984 shares in the last quarter. Blair William & Co. IL grew its holdings in shares of Vistagen Therapeutics by 29.2% in the 2nd quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock valued at $308,000 after buying an additional 20,000 shares during the period. Finally, Acadian Asset Management LLC bought a new stake in shares of Vistagen Therapeutics in the 1st quarter valued at $169,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, William Blair upgraded Vistagen Therapeutics to a “strong-buy” rating in a report on Friday, August 30th.

Vistagen Therapeutics Stock Performance

Shares of VTGN opened at $2.54 on Friday. The stock has a 50 day simple moving average of $2.99 and a 200 day simple moving average of $3.44. Vistagen Therapeutics, Inc. has a 52-week low of $2.52 and a 52-week high of $5.86. The firm has a market capitalization of $70.72 million, a PE ratio of -2.05 and a beta of 0.78.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.